Medinet Co
Medinet is a biotech company dedicated to creating innovative technologies and services that support next-generation medical care. They focus on regenerative and cell therapy, providing total solutions through their facilities and personnel, and aim to contribute to society by advancing medical technology and supporting patients and communities.
Industries
Nr. of Employees
medium (51-250)
Medinet Co
〒143-0006 Tokyo, Ota-ku, Heiwajima 6-1-1 TRC Center Building 9F
Patents
Products
Immuno-Cell Therapy
A treatment that uses a patient's own immune cells, activated and proliferated outside the body, to target and attack abnormal cells like cancer cells.
Regenerative Medical Products
Products distinct from pharmaceuticals and medical devices, developed for regenerative purposes, not classified as specified cell products.
Specified Cell Products
Products defined under the Act on the Safety of Regenerative Medicine, involving various tissues and cells for development and commercialization.
Shinagawa Cell Processing Facility (CPF)
A facility equipped to comply with Japanese, US, and European regulations for cell processing, offering manufacturing and processing services.
Technology Transfer and Process Development
Services that involve transferring technology and developing processes to create efficient manufacturing environments.
Quality Control and Quality Assurance
Systems and procedures to ensure the safety and quality of specified cell products and regenerative medical products.
Immuno-Cell Therapy
A treatment that uses a patient's own immune cells, activated and proliferated outside the body, to target and attack abnormal cells like cancer cells.
Regenerative Medical Products
Products distinct from pharmaceuticals and medical devices, developed for regenerative purposes, not classified as specified cell products.
Specified Cell Products
Products defined under the Act on the Safety of Regenerative Medicine, involving various tissues and cells for development and commercialization.
Shinagawa Cell Processing Facility (CPF)
A facility equipped to comply with Japanese, US, and European regulations for cell processing, offering manufacturing and processing services.
Technology Transfer and Process Development
Services that involve transferring technology and developing processes to create efficient manufacturing environments.
Quality Control and Quality Assurance
Systems and procedures to ensure the safety and quality of specified cell products and regenerative medical products.
Services
Contract production and cell-processing services for immune cell therapies, performed in facility cleanrooms for use by medical institutions and developers.
Contract manufacture of defined cell-processed products using somatic cells, adult stem cells and iPSC-derived materials for regenerative-medicine applications.
Development and manufacturing support for investigational regenerative-medicine products and clinical-trial materials, including production under applicable national regulations.
Operational management support for cell-processing facilities, including dispatch of trained technicians and technology-transfer assistance to customer sites.
Collection and storage service for resected tumor tissue for future therapeutic use or development.
Logistics and packaging optimized for the safe transport of cell-processing products, aligned to international guidance for infectious substances.
Contract production and cell-processing services for immune cell therapies, performed in facility cleanrooms for use by medical institutions and developers.
Contract manufacture of defined cell-processed products using somatic cells, adult stem cells and iPSC-derived materials for regenerative-medicine applications.
Development and manufacturing support for investigational regenerative-medicine products and clinical-trial materials, including production under applicable national regulations.
Operational management support for cell-processing facilities, including dispatch of trained technicians and technology-transfer assistance to customer sites.
Collection and storage service for resected tumor tissue for future therapeutic use or development.
Logistics and packaging optimized for the safe transport of cell-processing products, aligned to international guidance for infectious substances.
Expertise Areas
- Contract manufacturing (CMO) for cell therapies
- CDMO services for regenerative medicine and clinical trial materials
- Clinical cell-processing and cleanroom operations
- Process development and scale-up for cell production
Key Technologies
- Cell culture and expansion for therapeutic use
- Cleanroom-based GMP/GCTP processing
- Online environmental monitoring systems
- Barcode-based sample tracking and traceability
News & Updates
Video of the FY2025 second quarter financial results briefing session held on May 29, 2025.
Financial results briefing material for FY2025 second quarter, released on May 29, 2025.
A case report on immune checkpoint inhibitor and anti-cancer drug therapy being ineffective for kidney cancer, with immune cell therapy showing remarkable efficacy.
The company's Executive Fellow has been appointed as the Regional Vice-President Elect of the International Society for Cell and Gene Therapy.
Semi-annual report for FY2025, released on May 14, 2025.
Video of the FY2025 second quarter financial results briefing session held on May 29, 2025.
Financial results briefing material for FY2025 second quarter, released on May 29, 2025.
A case report on immune checkpoint inhibitor and anti-cancer drug therapy being ineffective for kidney cancer, with immune cell therapy showing remarkable efficacy.
The company's Executive Fellow has been appointed as the Regional Vice-President Elect of the International Society for Cell and Gene Therapy.
Semi-annual report for FY2025, released on May 14, 2025.